NUVA Related Analyst Ratings
-
WallachBeth Capital Starts NuVasive (NUVA) at Buy
-
Mizuho Securities Downgrades NuVasive (NUVA) to Neutral
-
BofA/Merrill Lynch Downgrades NuVasive (NUVA) to Neutral
-
Janney Montgomery Scott Starts NuVasive (NUVA) at Buy
-
RBC Capital Upgrades NuVasive (NUVA) to Sector Perform
-
Exact Target (ET), IMAX (IMAX) Among Barrington's Best Stock Ideas For 2013
-
BMO Capital Upgrades NuVasive (NUVA) to Market Perform
-
First Analysis Upgrades NuVasive (NUVA) to Overweight
-
Barclays Downgrades NuVasive (NUVA) to Equalweight
-
JMP Securities Downgrades NuVasive (NUVA) to Market Perform
-
Wells Fargo Downgrades NuVasive (NUVA) to Market Perform after Warning
-
First Analysis Downgrades NuVasive (NUVA) to Equal Weight after Warning
-
Summer Street Downgrades NuVasive (NUVA) to Neutral
-
Brean Murray Carret & Co. Downgrades NuVasive (NUVA) to Hold on Warning; Globus (GMED), Orthofix (OFIX) Benefit
-
RBC Capital Downgrades NuVasive (NUVA) to Underperform
-
BMO Capital Downgrades NuVasive (NUVA) to Underperform after Warning
-
Brean Murray Carret & Co. Starts NuVasive (NUVA) at Buy, Expectations Conservative
-
Northland Securities Starts NuVasive (NUVA) at Market Perform
-
Canaccord Genuity Maintains a 'Buy' on NuVasive (NUVA); Q2 Review
-
Wells Fargo Upgrades NuVasive (NUVA) to Outperform; Spine Market has Bottomed
-
First Analysis Downgrades NuVasive (NUVA) to Equal Weight
-
Leerink Swann Maintains an 'Outperform' on NuVasive (NUVA); 2012 Guidance Looking More and More Conservative
-
RBC Capital Upgrades NuVasive (NUVA) to Outperform
-
Barclays on Medical Supplies & Devices: Continue To Favor Stocks with Potential Product Catalyst (STJ, THOR, HWTR & NUVA)
-
Canaccord Genuity Reiterates a 'Buy' on NuVasive (NUVA); Raising PT on Continued Growth Across All Business Segments
-
William Blair Upgrades NuVasive (NUVA) to Outperform
-
Baird Upgrades NuVasive (NUVA) to Outperform
-
Wells Fargo Starts NuVasive (NUVA) at Market Perform; Facing Market and Competitive Headwinds
-
JMP Securities Upgrades NuVasive (NUVA) to Market Outperform
-
Jefferies Maintains a 'Buy' on NuVasive (NUVA) as 2012 Guidance Looks Achievable
-
Canaccord Genuity Maintains a 'Buy' on NuVasive (NUVA); Outpaces Market; Unique Asset at Cheap valuation
-
Craig-Hallum Downgrades NuVasive (NUVA) to Hold, Cuts Price Target to $16
-
Baird Downgrades NuVasive (NUVA) to Neutral
-
Canaccord Genuity Q4/11 Orthopedic Preview: Four Movers Over The Next Six Months
-
UPDATE - Canaccord Genuity Upgraded NuVasive (NUVA) to Buy; Top Quality Asset at Rock-Bottom Price
-
Canaccord Genuity Upgrades NuVasive (NUVA) to Buy
-
First Analysis Upgrades NuVasive (NUVA) to Overweight
-
Caris & Co. Upgrades NuVasive (NUVA) to Above Average
-
ThinkEquity Starts NuVasive (NUVA) at Buy
-
BMO Capital Downgrades NuVasive (NUVA) to Market Perform
-
Kaufman Bros. on Medical Technology - Keeping Things Simple as We Enter 2012
-
Barclays Maintains an 'Equalweight' on Medtronic (MDT); INFUSE in Focus at NASS
-
Rodman & Renshaw Downgrades NuVasive (NUVA) to Market Perform
-
Barclays Maintains an 'Overweight' on NuVasive (NUVA); Stable US Trends; Lower OUS/Biologics Revenue
-
Canaccord Genuity Maintains a 'Hold' on NuVasive (NUVA); Q3/11 Revenue Miss Apparent, One-time Charges Skew EPS, 2012 Still A Guess
-
William Blair Downgrades NuVasive (NUVA) to Market Perform
-
Jefferies Cuts Price Target on NuVasive (NUVA), Highlights Details with Medtronics (MDT)
-
Capstone Investments Upgrades NuVasive (NUVA) to Buy
-
UPDATE - Barclays Upgraded NuVasive (NUVA) to Overweight; Litigation Manageable
-
Barclays Upgrades NuVasive (NUVA) to Overweight
Back to NUVA Stock Lookup
